Mikkel Noerholm
Columbia University Medical Center
CancerInternal medicineUrologyPathologyOncologyGene expressionMolecular biologyMicrovesiclesBiopsyProstateMelanomaLiquid biopsyGene signatureUrineProstate cancerProstate biopsyExosomeCancer researchRNAMedicineBiologyPCA3
53Publications
12H-index
1,143Citations
Publications 55
Newest
The ability to discriminate indolent from clinically significant prostate cancer (PC) at the initial biopsy remains a challenge. The ExoDx Prostate (IntelliScore) (EPI) test is a noninvasive liquid biopsy that quantifies three RNA targets in urine exosomes. The EPI test stratifies patients for risk of high-grade prostate cancer (HGPC; ≥ Grade Group 2 [GG] PC) in men ≥ 50 years with equivocal prostate-specific antigen (PSA) (2–10 ng/mL). Here, we present a pooled meta-analysis from three independ...
Source
#1Gordon D. BrownH-Index: 108
#2Jason AlterH-Index: 4
Last. Grannum R. SantH-Index: 47
view all 9 authors...
Source
#2Michael J. DonovanH-Index: 35
Last. Ronald TutroneH-Index: 14
view all 8 authors...
Source
#1Ronald TutroneH-Index: 14
#2Michael J. DonovanH-Index: 35
Last. James M. McKiernanH-Index: 51
view all 8 authors...
Source
Source
Abstract Liquid biopsy in cancer has gained momentum in clinical research and is experiencing a boom for a variety of applications. There are significant efforts to utilize liquid biopsies in cancer for early detection and treatment stratification, as well as residual disease and recurrence monitoring. Although most efforts have used circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for this purpose, exosomes and other extracellular vesicles (EVs) have emerged as a platform with p...
Source
#2Gordon A. BrownH-Index: 24
view all 11 authors...
Source
#1James M. McKiernan (CUMC: Columbia University Medical Center)H-Index: 51
#2Mikkel NoerholmH-Index: 12
Last. Johan SkogH-Index: 33
view all 9 authors...
Background Initial prostate biopsy often fails to identify prostate cancer resulting in patient anxiety, especially when clinical features such as prostate specific antigen (PSA) remain elevated, leading to the need for repeat biopsies. Prostate biomarker tests, such as the ExoDx™ Prostate (IntelliScore), or EPI test, have been shown to provide individualized risk assessment of clinically significant prostate cancer at initial biopsy; however, the performance in the repeat biopsy setting is not ...
Source
#1Ronald Tutrone (Chesapeake Energy)H-Index: 14
#2Michael J. Donovan (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 35
Last. James M. McKiernan (CUMC: Columbia University Medical Center)H-Index: 51
view all 8 authors...
The ExoDx Prostate(IntelliScore) (EPI) test is a non-invasive risk assessment tool for detection of high-grade prostate cancer (HGPC) that informs whether to proceed with prostate biopsy. We sought to assess the impact of EPI on the decision to biopsy in a real-world clinical setting. We conducted a prospective, randomized, blinded, two-armed clinical utility study that enrolled 1094 patients with 72 urologists from 24 urology practices. Patients were considered for prostate biopsy at enrollment...
Source
#1Kay BrinkmanH-Index: 1
#2Lisa MeyerH-Index: 3
Last. Mikkel NoerholmH-Index: 12
view all 7 authors...
ABSTRACTIn addition to Circulating Tumour Cells (CTCs), cell-free DNA (cfDNA) and Extracellular Vesicles (EVs), the notion of “Tumour-Educated Platelets” (TEP) has recently emerged as a potential s...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.